Submitted by Anonymous (not verified) on 30 August 2023 - 10:46
Human medicines European public assessment report (EPAR): Bavencio, avelumab, Neuroendocrine Tumors, Date of authorisation: 18/09/2017, Revision: 16, Status: Authorised
Source: